CN1781530A - 一种绛芝益肝胶囊及其制备工艺 - Google Patents
一种绛芝益肝胶囊及其制备工艺 Download PDFInfo
- Publication number
- CN1781530A CN1781530A CN 200410097795 CN200410097795A CN1781530A CN 1781530 A CN1781530 A CN 1781530A CN 200410097795 CN200410097795 CN 200410097795 CN 200410097795 A CN200410097795 A CN 200410097795A CN 1781530 A CN1781530 A CN 1781530A
- Authority
- CN
- China
- Prior art keywords
- liver
- drying
- spray drying
- ganoderma
- jiangzhi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 44
- 239000002775 capsule Substances 0.000 title claims abstract description 20
- 239000009427 jiangzhi Substances 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims description 7
- 230000008569 process Effects 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 241000222336 Ganoderma Species 0.000 claims abstract description 19
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 238000001694 spray drying Methods 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 229920002472 Starch Polymers 0.000 claims abstract description 8
- 239000008107 starch Substances 0.000 claims abstract description 8
- 235000019698 starch Nutrition 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 7
- 238000012856 packing Methods 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 229920001353 Dextrin Polymers 0.000 claims abstract description 4
- 239000004375 Dextrin Substances 0.000 claims abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- 235000019425 dextrin Nutrition 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 23
- 239000000047 product Substances 0.000 claims description 21
- 238000005516 engineering process Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 12
- 241001506047 Tremella Species 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 241001614291 Anoplistes Species 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 230000004087 circulation Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 238000004445 quantitative analysis Methods 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 235000015424 sodium Nutrition 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 41
- 239000008280 blood Substances 0.000 abstract description 41
- 230000006870 function Effects 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 12
- 238000009835 boiling Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 241000735234 Ligustrum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 22
- 150000002632 lipids Chemical class 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 16
- 230000000144 pharmacologic effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 201000005577 familial hyperlipidemia Diseases 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000002443 hepatoprotective effect Effects 0.000 description 9
- 231100000753 hepatic injury Toxicity 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 4
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 4
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 动物数(只) | 体重(g)(X±SD) | 增重(g)(X±SD) | |
试验前 | 试验末 | |||
高脂对照0.19g/kg0.38g/kg1.13g/kg | 10101010 | 324.2±20.1327.4±9.2324.1±14.8321.0±17.5 | 365.7±16.4367.1±12.1360.7±18.3359.1±13.8 | 41.5±21.839.7±17.136.6±19.038.1±19.3 |
FP | 0.2700.846 | 0.6270.602 | 0.1110.953 |
组别 | 动物数(只) | TC(mmol/L)(X±SD) | |
试验前 | 试验末 | ||
高脂对照0.19g/kg0.38g/kg1.13g/kg | 10101010 | 3.76±0.633.76±0.573.76±0.563.76±0.57 | 4.10±0.693.55±0.61*2.89±0.54*2.68±0.52* |
FP | 4.65E-051.000 | 11.9181.44E-05 |
组别 | 动物数(只) | TG(mmol/L)(X±SD) | |
试验前 | 试验末 | ||
高脂对照0.19g/kg0.38g/kg1.13g/kg | 10101010 | 1.64±0.231.60±0.231.66±0.241.61±0.29 | 1.68±0.181.21±0.41*1.22±0.26*1.09±0.24* |
FP | 0.1220.946 | 8.3140.0002 |
组别 | 动物数(只) | HDL-C(mg/dL)(X±SD) | |
试验前 | 试验末 | ||
高脂对照 | 10 | 60.39±13.92 | 73.09±12.83 |
0.19g/kg0.38g/kg1.13g/kg | 101010 | 63.82±11.2858.80±11.7963.51±12.04 | 84.21±20.6669.34±19.2470.81±12.06 |
FP | 0.3940.758 | 1.6430.197 |
组别 | 动物数 | 初始体重 | 中期体重 | 终期体重 |
正常对照CCL4模型低剂量中剂量高剂量 | 1010101010 | 19±0.919±0.819±.0.919±0.819±0.9 | 27±1.728±1.727±1.227±1.728±1.4 | 37±1.537±1.034±2.336±3.836±2.3 |
组别 | 动物数(只) | 谷丙转氨酶(IU/L) | 谷草转氨酶(IU/L) | 白/球蛋白比例 |
正常对照CCL4模型低剂量中剂量高剂量 | 1010101010 | 62±11*831±133826±162486±104*383±67* | 88±8*953±263732±234464±100*168±25* | 1.77±0.521.92±0.501.82±0.522.02±0.851.85±0.53 |
组别 | 动物数 | 颗粒变性 | 水样变性 | 气球变性 | 脂肪变性 | 胞浆凝聚 | 细胞坏死 | 炎症细胞浸润 | 总分 | 平均分 |
对照CCL4模型低剂量中剂量高剂量 | 1010101010 | 1512121314 | 1216121211 | 0141097 | 010874 | 034262424 | 034272424 | 214131110 | 2913410810094 | 2.9±0.9*13.4±3.110.8±2.310.0±3.09.4±2.6* |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100977959A CN100340266C (zh) | 2004-12-03 | 2004-12-03 | 一种降脂益肝的胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100977959A CN100340266C (zh) | 2004-12-03 | 2004-12-03 | 一种降脂益肝的胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1781530A true CN1781530A (zh) | 2006-06-07 |
CN100340266C CN100340266C (zh) | 2007-10-03 |
Family
ID=36772402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100977959A Expired - Fee Related CN100340266C (zh) | 2004-12-03 | 2004-12-03 | 一种降脂益肝的胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100340266C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101757265B (zh) * | 2008-10-24 | 2012-03-21 | 常州善美药物研究开发中心有限公司 | 一种治疗迁延性肝炎的中药组合物及其制备方法 |
CN103202377A (zh) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | 一种清肝(酒精肝、脂肪肝)茶及其制备方法 |
CN103211058A (zh) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | 一种辅助降血脂的保健茶颗粒冲剂及其制备方法 |
CN105267488A (zh) * | 2014-12-26 | 2016-01-27 | 完美(中国)有限公司 | 一种辅助降血脂和护肝的中药组合物及其制品 |
CN108355021A (zh) * | 2018-05-17 | 2018-08-03 | 福建省中医药研究院(福建省青草药开发服务中心) | 一种改善肝脏指标牛樟芝制品及其制作方法 |
CN108618150A (zh) * | 2018-06-12 | 2018-10-09 | 三明市园艺学会 | 一种护肝降脂胶囊保健品及其制作工艺 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1371713A (zh) * | 2002-03-25 | 2002-10-02 | 刘振顺 | 一粒丹 |
CN1371714A (zh) * | 2002-03-25 | 2002-10-02 | 孟范英 | 愈肝散 |
-
2004
- 2004-12-03 CN CNB2004100977959A patent/CN100340266C/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101757265B (zh) * | 2008-10-24 | 2012-03-21 | 常州善美药物研究开发中心有限公司 | 一种治疗迁延性肝炎的中药组合物及其制备方法 |
CN103202377A (zh) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | 一种清肝(酒精肝、脂肪肝)茶及其制备方法 |
CN103211058A (zh) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | 一种辅助降血脂的保健茶颗粒冲剂及其制备方法 |
CN105267488A (zh) * | 2014-12-26 | 2016-01-27 | 完美(中国)有限公司 | 一种辅助降血脂和护肝的中药组合物及其制品 |
CN108355021A (zh) * | 2018-05-17 | 2018-08-03 | 福建省中医药研究院(福建省青草药开发服务中心) | 一种改善肝脏指标牛樟芝制品及其制作方法 |
CN108618150A (zh) * | 2018-06-12 | 2018-10-09 | 三明市园艺学会 | 一种护肝降脂胶囊保健品及其制作工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN100340266C (zh) | 2007-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20230057438A (ko) | 진세노사이드 Rg3과 진세노사이드 Rg5의 조성물 및 항종양 효과를 포함하는 이의 약학적 용도 | |
CN1813961A (zh) | 一种用于治疗便秘的药物组合物 | |
CN1275639C (zh) | 一种治疗妇科习惯性流产和先兆性流产疾病的药物及其制备方法 | |
CN106667915A (zh) | 一种用于治疗仔猪腹泻的黄芩苷铝干混悬剂 | |
CN106362020B (zh) | 一种具有改善通便作用的松花粉组合物及其制备方法 | |
CN100340266C (zh) | 一种降脂益肝的胶囊及其制备方法 | |
CN100336537C (zh) | 一种抗疲劳增强免疫力的中药组合物及其制备方法 | |
CN1283281C (zh) | 一种含酸枣仁、灵芝、人参叶药物组合物及其制备和应用 | |
CN101926861A (zh) | 用于增强非特异性免疫功能的中药兽用药的制备方法 | |
CN103463382B (zh) | 一种治疗便秘的中药及其制备方法与应用 | |
CN110721289A (zh) | 仁术健胃颗粒的制备方法 | |
CN101912452A (zh) | 用于增强非特异性免疫功能的兽用中药组合物及其应用 | |
CN1218745C (zh) | 一种保肝护肝及调节血脂的保健食品及其制备方法 | |
CN103735621A (zh) | 一种具有降血脂和增强免疫力作用的中药组合物 | |
CN110664905A (zh) | 一种用于祛风散寒的中药制剂及其制备方法 | |
CN114533817A (zh) | 一种改善血糖和/或血脂的组合物及其应用 | |
CN1199683C (zh) | 一种降血脂和延缓衰老药物组合物及药物 | |
CN1857378A (zh) | 野生猕猴桃复方吞咽片及其制备方法 | |
CN100525804C (zh) | 具有减肥作用的中药复方制剂 | |
CN1248715C (zh) | 一种健胃药物及其制备方法 | |
CN111388584A (zh) | 一种治疗阳痿的组合物及其制备方法 | |
CN110420258A (zh) | 一种具有壮阳功效的金樱根提取物及其制备方法和用途 | |
CN1509751A (zh) | 一种具有改善睡眠作用的药物组合物 | |
TWI440465B (zh) | 用以降血脂的中草藥萃取混合物及其醫藥組合物 | |
CN102631487B (zh) | 提高免疫力、抗疲劳的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUO XIULIANG Free format text: FORMER OWNER: CHEN JIANWEI Effective date: 20130620 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Guo Xiuliang Inventor before: Chen Jianwei |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHEN JIANWEI TO: GUO XIULIANG |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130620 Address after: 323700, Lane 53, West Street, Longquan, Zhejiang Patentee after: Guo Xiuliang Address before: 323700 Zhejiang province Longquan Jiangbin Road No. 101 Patentee before: Chen Jianwei |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071003 Termination date: 20161203 |
|
CF01 | Termination of patent right due to non-payment of annual fee |